To test whether the positive correlation between CA-125 and tenascin-X in the initial patient study was true at the time of diagnosis in a larger population, we examined the level of CA-125 and tenascin-X in serum of healthy, benign ovarian cancer, and high-grade serous ovarian cancer patients by ELISA and correlated them (Figure 3). The gene discussed is TNXB; the disease is ovarian serous adenocarcinoma.